MCID: HMR003
MIFTS: 59

Hemorrhagic Disease

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Hemorrhagic Disease

MalaCards integrated aliases for Hemorrhagic Disease:

Name: Hemorrhagic Disease 12 15
Hemorrhagic Diathesis 12 6
Hemorrhagic Disorders 44 70
Haemorrhagic Disorders 6
Hemorrhagic Diseases 54
Bleeding Tendency 70

Classifications:



External Ids:

Disease Ontology 12 DOID:2213
ICD9CM 34 287.9
MeSH 44 D006474
SNOMED-CT 67 268884000
ICD10 32 D68.3 D69.9
UMLS 70 C0019087 C1458140

Summaries for Hemorrhagic Disease

MalaCards based summary : Hemorrhagic Disease, also known as hemorrhagic diathesis, is related to vitamin k deficiency bleeding and factor xi deficiency, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Hemorrhagic Disease is F8 (Coagulation Factor VIII), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Antidotes and Charcoal have been mentioned in the context of this disorder. Affiliated tissues include prostate, endothelial and liver, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Hemorrhagic Disease

Diseases in the Hemorrhagic Disease family:

Rare Hemorrhagic Disorder Due to an Acquired Coagulation Factor Defect Hemorrhagic Disease Due to Alpha-1-Antitrypsin Pittsburgh Mutation
Rare Hemorrhagic Disorder Due to a Platelet Anomaly Rare Hemorrhagic Disorder Due to a Coagulation Factors Defect
Rare Hemorrhagic Disorder Rare Hemorrhagic Disorder Due to an Acquired Platelet Anomaly
Rare Hemorrhagic Disorder Due to a Constitutional Thrombocytopenia Rare Hemorrhagic Disorder Due to a Qualitative Platelet Defect
Rare Hemorrhagic Disorder Due to a Constitutional Platelet Anomaly Rare Hemorrhagic Disorder Due to a Constitutional Coagulation Factors Defect

Diseases related to Hemorrhagic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 323)
# Related Disease Score Top Affiliating Genes
1 vitamin k deficiency bleeding 32.6 F9 F8 F7
2 factor xi deficiency 32.4 VWF F9 F8 F7 F11-AS1 F11
3 factor x deficiency 32.3 F9 F7 F11
4 factor vii deficiency 32.3 F9 F8 F7
5 alpha-2-plasmin inhibitor deficiency 32.0 SERPINF2 F7
6 von willebrand's disease 31.7 VWF ITGA2B F9 F8 F7 F11
7 afibrinogenemia, congenital 31.5 VWF SERPINF2 FGG FGA F8 F7
8 hemophilia b 31.2 VWF FGA F9 F8 F7 F11
9 thrombosis 31.2 VWF SERPINF2 P2RY12 ITGA2B FGG FGA
10 thrombocytopenic purpura, autoimmune 31.1 ITGA2B F8 ADAMTS13
11 hemophilia 31.1 F9 F8 F7
12 disseminated intravascular coagulation 31.1 VWF SERPINF2 FGA F9 F7 ADAMTS13
13 factor xii deficiency 31.1 VWF F9 F7 F11
14 thrombocytopenia 31.0 VWF SLFN14 RUNX1 P2RY12 MYH9 MED12L
15 blood coagulation disease 31.0 VWF SERPINF2 P2RY12 MYH9 ITGA2B GBA
16 thrombophilia 30.9 VWF SERPINF2 FGG FGA F9 F8
17 blood platelet disease 30.9 VWF RUNX1 MYH9 ITGA2B GBA F8
18 cerebrovascular disease 30.9 VWF ITGA2B FGA F8 F7 ADAMTS13
19 acquired von willebrand syndrome 30.8 VWF F8 F7 ADAMTS13
20 factor xiii deficiency 30.8 VWF SERPINF2 F8 F7
21 acquired thrombocytopenia 30.8 MYH9 ITGA2B F11
22 factor v deficiency 30.8 VWF F9 F8 F7
23 bernard-soulier syndrome 30.7 VWF P2RY12 MYH9 ITGA2B FGA F9
24 qualitative platelet defect 30.7 VWF F7
25 purpura 30.7 VWF ITGA2B ADAMTS13
26 thrombophlebitis 30.6 VWF SERPINF2 F8 F7
27 hemarthrosis 30.6 VWF F9 F8 F7 F11
28 factor viii deficiency 30.6 VWF F9 F8 F7 F11
29 pulmonary embolism 30.5 VWF SERPINF2 F9 F8
30 prothrombin deficiency 30.5 F9 F8 F7 F11
31 hemophilia a 30.5 VWF F9 F8 F7
32 thrombophilia due to thrombin defect 30.5 VWF FGA F8
33 thrombotic thrombocytopenic purpura 30.4 VWF SERPINF2 ADAMTS13
34 active peptic ulcer disease 30.4 VWF F7
35 bombay phenotype 30.3 VWF ADAMTS13
36 hermansky-pudlak syndrome 1 11.5
37 hermansky-pudlak syndrome 11.3
38 hermansky-pudlak syndrome 2 11.3
39 hermansky-pudlak syndrome 3 11.3
40 hermansky-pudlak syndrome 4 11.3
41 hermansky-pudlak syndrome 5 11.3
42 hermansky-pudlak syndrome 6 11.3
43 hermansky-pudlak syndrome 7 11.3
44 hermansky-pudlak syndrome 8 11.3
45 hermansky-pudlak syndrome 9 11.3
46 antithrombin, familial hemorrhagic diathesis due to 11.1
47 hemorrhagic disease due to alpha-1-antitrypsin pittsburgh mutation 11.1
48 thrombophilia due to activated protein c resistance 11.1
49 infantile liver failure syndrome 11.1
50 lujo hemorrhagic fever 10.9

Comorbidity relations with Hemorrhagic Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease

Graphical network of the top 20 diseases related to Hemorrhagic Disease:



Diseases related to Hemorrhagic Disease

Symptoms & Phenotypes for Hemorrhagic Disease

UMLS symptoms related to Hemorrhagic Disease:


angina pectoris; chest pain; edema; abnormal bruising

MGI Mouse Phenotypes related to Hemorrhagic Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.22 ETV6 F11 F7 F9 FGA FGG
2 hematopoietic system MP:0005397 10.2 ADAMTS13 ETV6 F11 F8 F9 FGA
3 homeostasis/metabolism MP:0005376 10.16 ADAMTS13 ETV6 F11 F7 F8 F9
4 embryo MP:0005380 10.02 ETV6 F9 FGA FGG FLI1 GFI1B
5 immune system MP:0005387 10 ADAMTS13 ETV6 F11 F8 F9 FGA
6 liver/biliary system MP:0005370 9.5 ETV6 F11 F9 FGA FLI1 GBA
7 mortality/aging MP:0010768 9.5 ADAMTS13 ETV6 F11 F7 F8 F9

Drugs & Therapeutics for Hemorrhagic Disease

Drugs for Hemorrhagic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antidotes Phase 4
2 Charcoal Phase 4
3 Coagulants Phase 4
4
Tranexamic Acid Approved Phase 3 1197-18-8 5526
5
Aprotinin Approved, Investigational, Withdrawn Phase 3 9087-70-1 16130295
6
Polidocanol Approved Phase 2, Phase 3 9002-92-0
7 Serine Proteinase Inhibitors Phase 3
8
protease inhibitors Phase 3
9 HIV Protease Inhibitors Phase 3
10 Trypsin Inhibitors Phase 3
11 Autoantibodies Phase 2, Phase 3
12 Pharmaceutical Solutions Phase 2, Phase 3
13 Sclerosing Solutions Phase 2, Phase 3
14 Cathartics Phase 2, Phase 3
15 Laxatives Phase 2, Phase 3
16
Serine Investigational, Nutraceutical Phase 3 56-45-1 5951
17
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
18
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
19
Pembrolizumab Approved Phase 2 1374853-91-4
20 Janus Kinase Inhibitors Phase 1, Phase 2
21 Analgesics, Non-Narcotic Phase 2
22 Analgesics Phase 2
23 Cyclooxygenase Inhibitors Phase 2
24 Antirheumatic Agents Phase 2
25 Anti-Inflammatory Agents Phase 2
26 Anti-Inflammatory Agents, Non-Steroidal Phase 2
27 Immunologic Factors Phase 2
28 Factor VIII Phase 1, Phase 2
29
tannic acid Approved 1401-55-4
30
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
31
Ibuprofen Approved 15687-27-1 3672
32
Zidovudine Approved 30516-87-1 35370
33
Sofosbuvir Approved 1190307-88-0 45375808
34
Milk thistle Approved, Experimental, Investigational 65666-07-1
35
Ribavirin Approved 36791-04-5 37542
36
Furosemide Approved, Vet_approved 54-31-9 3440
37
Spironolactone Approved 1952-01-7, 52-01-7 5833
38
Vitamin K1 Approved, Investigational 84-80-0 5284607
39
Xylometazoline Approved, Investigational 526-36-3 5709
40
Nitroglycerin Approved, Investigational 55-63-0 4510
41
Warfarin Approved 81-81-2 54678486 6691
42
Apixaban Approved 503612-47-3 10182969
43
Rivaroxaban Approved 366789-02-8
44
Edoxaban Approved 480449-70-5
45
Thrombin Approved, Investigational
46
Menadione Approved, Nutraceutical 58-27-5 4055
47 Menaquinone Investigational 1182-68-9
48
Dabigatran Investigational 211914-51-1
49 Anticoagulants
50 Antimetabolites

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
2 Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants Unknown status NCT02969746 Phase 4 Activated Charcoal
3 Conventional Versus Point-of-care Based Coagulation Management in Cardiac Surgery Patients Suffering From Increased Bleeding Tendency - a Prospective and Randomized Study Completed NCT00997841 Phase 4
4 Post-marketing Investigation (PMI) to Assess Safety and Efficacy of Jivi (BAY 94-9027) Treatment in Participants With Hemophilia A Active, not recruiting NCT04085458 Phase 4 Damoctocog alfa pegol (Jivi, BAY94-9027)
5 The Influence of High-Dose Aprotinin and Tranexamic Acid on Bleeding Tendency and Allogeneic Blood Transfusion in Patients Undergoing Primary Aortic Valve Replacement or Coronary Artery Revascularization Unknown status NCT00396760 Phase 3 aprotinin or tranexamic acid
6 Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies Completed NCT01178294 Phase 2, Phase 3
7 Cooperative Study of Factor VIII Inhibitors Completed NCT00000582 Phase 3 factor ix
8 Sclerotherapy With Polidocanol Foam In The Management Of First, Second And Third-Grade Hemorrhoidal Disease In Patients With Bleeding Disorders: A Prospective Cohort Study Active, not recruiting NCT04188171 Phase 2, Phase 3
9 Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Patients With Congenital Hemophilia A With Factor VIII Inhibitors Terminated NCT01434511 Phase 3
10 A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis Completed NCT01787552 Phase 1, Phase 2 LDE225;INC424
11 PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer: a Single Arm Phase II Study Recruiting NCT03638297 Phase 2 PD-1 antibody + cox inhibitor
12 A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting. Recruiting NCT04309084 Phase 1, Phase 2
13 Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors Active, not recruiting NCT03734588 Phase 1, Phase 2
14 A Single-centre, Randomised, Double-blind, Two-way Cross-over Trial Investigating the Bio-equivalence in Healthy Male Subjects of NovoSeven (CP-rFVIIa) and a Formulation of NovoSeven Stable at 25°C (VII25) Completed NCT01561417 Phase 1 activated recombinant human factor VII;activated recombinant human factor VII
15 The Correlation Between The New Sepsis Scores - SOFA, Quick SOFA and Calibrated Automated Thrombogram Values Unknown status NCT02953002
16 A Mobile Health Application to Improve Anticoagulation Care in Atrial Fibrillation: Randomized Controlled Trial Unknown status NCT03174093
17 Input of a Multidisciplinary Device Including a Psychological Approach, to Accompany the Announce of Diagnosis for Young Children With Serious Constitutional Hemorrhagic Disease and Their Families Completed NCT02834130
18 Study of Bleeding Tendency, Platelet Function, and Pharmacokinetics of Azidothymidine (AZT) and Motrin (Ibuprofen) in HIV-Infected Hemophiliacs Completed NCT00002276 Ibuprofen;Zidovudine
19 Real Life Experience in the Management of HCV Related Decompensated Cirrhosis With Direct Antiviral Agents Completed NCT03547895 Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol);vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion
20 Standardisation of Investigations of Mild Bleeding Disorders Completed NCT02329899
21 Gastrointestinal Endoscopy in Patients With Prothrombotic Conditions: A Prospective, Multicentre, and Observational Registry Completed NCT03669068
22 Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study Completed NCT02376777
23 Determination of Fibrin Activity in Plasma on STA-R® Prototype Completed NCT02856789
24 Endothelial Dysfunction Leads to Bleeding Diathesis Completed NCT04553172
25 Efficacy of NovoSeven® (Activated Recombinant Human Factor VII): Non-interventional Study in Patients With Congenital Haemophilia With Inhibitors, Acquired Haemophilia, Factor FVII Deficiency, and Glanzmann's Thrombasthenia Completed NCT00697320 eptacog alfa (activated)
26 Adherence and the Role of Coagulation Assays in Patients Treated With Dabigatran Etexilate for Non-valvular Atrial Fibrillation Completed NCT03280368
27 Blood Gas and Bleeding Disorders in Healthy Volunteers Exposed to Nitroglycerin and Nitrogen Compounds of Blasting Gelatin: a Field Report During a Cave Accident Completed NCT04201860
28 Novel Oral Anticoagulants in Oral and Maxillofacial Surgery: Impact on Bleeding Tendency, Surgical Difficulty and Post-operative Complications Recruiting NCT04662515 Dabigatran;Rivaroxaban;Apixaban;Edoxaban;Warfarin
29 Bleeding in Thrombocytopenia Explained Recruiting NCT03505086
30 Coagulation Monitoring in Patients on Extracorporeal Membrane Oxygenation Hämostaseologisches Monitoring Bei Patienten Mit Extrakorporaler Membranoxygenierung Recruiting NCT03642912
31 Rare Bleeding Disorders in the Netherlands Recruiting NCT03347591
32 A Multi-Center, Observational Study in Males With Hemophilia A Active, not recruiting NCT03876301 Standard of Care FVIII Replacement therapy
33 ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders Enrolling by invitation NCT04398628
34 Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders. Enrolling by invitation NCT03834727
35 Medication Exposure in Older Patients (AGEd > 65 Years) With Constitutional HEMORRHagic Disease (Haemophilia or Willebrand Disease). Not yet recruiting NCT04282486

Search NIH Clinical Center for Hemorrhagic Disease

Cochrane evidence based reviews: hemorrhagic disorders

Genetic Tests for Hemorrhagic Disease

Anatomical Context for Hemorrhagic Disease

MalaCards organs/tissues related to Hemorrhagic Disease:

40
Prostate, Endothelial, Liver, Kidney, Spleen, Breast, Bone Marrow

Publications for Hemorrhagic Disease

Articles related to Hemorrhagic Disease:

(show top 50) (show all 1879)
# Title Authors PMID Year
1
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
2
Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. 6
31064749 2019
3
Gross hematuria due to acquired haemophilia in hereditary hemorrhagic telangiectasia. 61 54
18832920 2008
4
Genetic diagnosis of haemophilia and other inherited bleeding disorders. 54 61
16684001 2006
5
[Type 2B and pseudo type 2B Von Willebrand disease; a report of three cases]. 54 61
16176858 2006
6
High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. 61 54
16091456 2005
7
Carrier detection and prenatal diagnosis of hemophilia in developing countries. 61 54
16276463 2005
8
[Coagulation disorders following severe trauma: surgeon's role in prevention]. 54 61
15605516 2004
9
Severe congenital factor X deficiency with intracranial bleeding in two siblings. 54 61
15036435 2004
10
Factor VIII inhibitor with catalytic activity towards factor VIII. 54 61
11187883 2000
11
[Study on genetic mutations of the vWF in type 2A von Willebrand disease]. 61 54
10932002 2000
12
Catalytic activity of antibodies against factor VIII in patients with hemophilia A. 54 61
10470082 1999
13
Hemorrhagic and thrombotic disorders due to factor V deficiencies and abnormalities: an updated classification. 54 61
9597197 1998
14
Novel treatments for hemophilia through rebalancing of the coagulation cascade. 61
33577709 2021
15
Outbreak of rabbit hemorrhagic disease virus 2 in the southwestern United States: first detections in southern California. 61
33797311 2021
16
Different Chinese herbal medicine therapy for idiopathic thrombocytopenic purpura: A protocol for systematic review and Bayesian network meta-analysis. 61
33787633 2021
17
An Unusual Presentation of Hemorrhagic Disease in an Infant: A Probable Case of Abetalipoproteinemia. 61
32433446 2021
18
Serological and molecular study of Crimean-Congo Hemorrhagic Fever Virus in cattle from selected districts in Uganda. 61
33515661 2021
19
Reduced intracellular antioxidant capacity in platelets contributes to primary immune thrombocytopenia via ROS-NLRP3-caspase-1 pathway. 61
33383234 2021
20
Antihuman CD44 antibody BJ18 inhibits platelet phagocytosis by correcting aberrant FcɣR expression and M1 polarization in immune thrombocytopenia. 61
33690000 2021
21
Integrated mRNA and microRNA Transcriptome Sequencing Characterizes Sequence Variants and mRNA-microRNA Regulatory Networks in Grass Carp Fibroblasts Infected with Virulent and Attenuated GCRV. 61
33748916 2021
22
Virus-infected peripheral blood plasmablasts in a patient with severe fever with thrombocytopenia syndrome. 61
33222048 2021
23
Vector Competence of Florida Culicoides insignis (Diptera: Ceratopogonidae) for Epizootic Hemorrhagic Disease Virus Serotype-2. 61
33807536 2021
24
Spatial Analysis of the 2017 Outbreak of Hemorrhagic Disease and Physiographic Region in the Eastern United States. 61
33806137 2021
25
Randomly primed, strand-switching, MinION-based sequencing for the detection and characterization of cultured RNA viruses. 61
33357075 2021
26
Ultrasound Findings and Laboratory Predictors of Early Mortality in Patients With Severe Yellow Fever. 61
33703928 2021
27
Immunity against Lagovirus europaeus and the Impact of the Immunological Studies on Vaccination. 61
33805607 2021
28
Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012-2019. 61
33809204 2021
29
Dry Formulation of Virus-Like Particles in Electrospun Nanofibers. 61
33802376 2021
30
African Swine Fever Laboratory Diagnosis-Lessons Learned from Recent Animal Trials. 61
33562103 2021
31
Elephant Endotheliotropic Herpesvirus Is Omnipresent in Elephants in European Zoos and an Asian Elephant Range Country. 61
33670367 2021
32
Genomic insights into a population of introduced European rabbits Oryctolagus cuniculus in Australia and the development of genetic resistance to rabbit hemorrhagic disease virus. 61
33560563 2021
33
Establishment of a cell line from swim bladder of the Grass carp (Ctenopharyngodon idellus) for propagation of Grass Carp Reovirus Genotype II. 61
33460745 2021
34
Surgical revascularization for Moyamoya disease in the United States: A cost-effectiveness analysis. 61
33540961 2021
35
Long-term treatment with thalidomide for severe recurrent hemorrhage from intestinal angiodysplasia in Glanzmann Thrombasthenia. 61
32200672 2021
36
Swift and Reliable "Easy Lab" Methods for the Sensitive Molecular Detection of African Swine Fever Virus. 61
33669073 2021
37
An immortalized porcine macrophage cell line competent for the isolation of African swine fever virus. 61
33637799 2021
38
X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers. 61
33082527 2021
39
Oral Vaccination of Grass Carp (Ctenopharyngodon idella) with Baculovirus-Expressed Grass Carp Reovirus (GCRV) Proteins Induces Protective Immunity against GCRV Infection. 61
33445494 2021
40
Recombinant Baculovirus-Produced Grass Carp Reovirus Virus-Like Particles as Vaccine Candidate That Provides Protective Immunity against GCRV Genotype II Infection in Grass Carp. 61
33466933 2021
41
IDENTIFICATION OF TWO LETHAL CASES OF ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS HEMORRHAGIC DISEASE IN SUMATRAN ELEPHANT CALVES IN INDONESIA. 61
33480579 2021
42
The Effect of Maternal Antibodies on Clinical Response to Infection with Epizootic Hemorrhagic Disease Virus in White-Tailed Deer (Odocoileus virginianus) Fawns. 61
33635998 2021
43
SPATIAL VARIATION OF WHITE-TAILED DEER (ODOCOILEUS VIRGINIANUS) POPULATION IMPACTS AND RECOVERY FROM EPIZOOTIC HEMORRHAGIC DISEASE. 61
33635976 2021
44
Resource Selection by Wild and Ranched White-Tailed Deer (Odocoileus virginianus) during the Epizootic Hemorrhagic Disease Virus (EHDV) Transmission Season in Florida. 61
33467117 2021
45
EVIDENCE OF EPIZOOTIC HEMORRHAGIC DISEASE VIRUS AND BLUETONGUE VIRUS EXPOSURE IN NONNATIVE RUMINANT SPECIES IN NORTHERN FLORIDA. 61
33480554 2021
46
Coding-Complete Genome Sequences of Emerging Rabbit Hemorrhagic Disease Virus Type 2 Isolates Detected in 2020 in the United States. 61
33414291 2021
47
The identification and determination of toxin genes of Vibrio strains causing hemorrhagic disease on red drum (Sciaenops ocellatus) using PCR. 61
33398427 2021
48
Viruses for Landscape-Scale Therapy: Biological Control of Rabbits in Australia. 61
33108654 2021
49
Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates. 61
33790899 2021
50
The first complete genome sequence of the African swine fever virus genotype X and serogroup 7 isolated in domestic pigs from the Democratic Republic of Congo. 61
33478547 2021

Variations for Hemorrhagic Disease

ClinVar genetic disease variations for Hemorrhagic Disease:

6 (show top 50) (show all 214)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 VWF NM_000552.4(VWF):c.4453del (p.Val1485fs) Deletion Pathogenic 100360 rs61750095 GRCh37: 12:6128131-6128131
GRCh38: 12:6018965-6018965
2 SERPINF2 NM_000934.3(SERPINF2):c.561_565del (p.Lys189fs) Deletion Pathogenic 626930 rs1597325785 GRCh37: 17:1650652-1650656
GRCh38: 17:1747358-1747362
3 F9 NM_000133.3(F9):c.276del (p.Asp93fs) Deletion Pathogenic 627047 rs1603264300 GRCh37: X:138619543-138619543
GRCh38: X:139537384-139537384
4 VWF NM_000552.4(VWF):c.7080C>A (p.Cys2360Ter) SNV Pathogenic 627363 rs111597150 GRCh37: 12:6092317-6092317
GRCh38: 12:5983151-5983151
5 F8 NM_000132.3(F8):c.6685C>T (p.Leu2229Phe) SNV Pathogenic 627359 rs1603431508 GRCh37: X:154090031-154090031
GRCh38: X:154861756-154861756
6 VWF NM_000552.4(VWF):c.2435del (p.Pro812fs) Deletion Pathogenic 303 rs62643632 GRCh37: 12:6153464-6153464
GRCh38: 12:6044298-6044298
7 F11-AS1 , F11 NM_000128.3(F11):c.1556G>A (p.Trp519Ter) SNV Pathogenic 188887 rs201007090 GRCh37: 4:187207644-187207644
GRCh38: 4:186286490-186286490
8 F11 NM_000128.3(F11):c.408C>A (p.Cys136Ter) SNV Pathogenic 188914 rs143648758 GRCh37: 4:187195352-187195352
GRCh38: 4:186274198-186274198
9 FGA NM_021871.4(FGA):c.104G>A (p.Arg35His) SNV Pathogenic 16404 rs121909607 GRCh37: 4:155510665-155510665
GRCh38: 4:154589513-154589513
10 SLFN14 NM_001129820.2(SLFN14):c.3_4insCTAGTCGACTATA (p.Glu2fs) Insertion Pathogenic 988815 GRCh37: 17:33885078-33885079
GRCh38: 17:35558059-35558060
11 ADAMTS13 NM_139027.6(ADAMTS13):c.1315G>T (p.Glu439Ter) SNV Pathogenic 988818 GRCh37: 9:136301955-136301955
GRCh38: 9:133436835-133436835
12 GFI1B NM_001377304.1(GFI1B):c.814+1G>A SNV Pathogenic 988821 GRCh37: 9:135865295-135865295
GRCh38: 9:132989908-132989908
13 ITGA2B NM_000419.5(ITGA2B):c.2176A>T (p.Lys726Ter) SNV Pathogenic 988822 GRCh37: 17:42455077-42455077
GRCh38: 17:44377709-44377709
14 NBEAL2 NM_015175.3(NBEAL2):c.6801+1G>C SNV Pathogenic 988824 GRCh37: 3:47047338-47047338
GRCh38: 3:47005848-47005848
15 VWF NM_000552.4(VWF):c.2516del (p.Gly839fs) Deletion Pathogenic 100225 rs61748481 GRCh37: 12:6145584-6145584
GRCh38: 12:6036418-6036418
16 MED12L , P2RY12 NM_022788.5(P2RY12):c.772C>A (p.Pro258Thr) SNV Pathogenic 988856 GRCh37: 3:151055862-151055862
GRCh38: 3:151338074-151338074
17 SMAD4 NM_005359.6(SMAD4):c.904+1_904+2insGCCTGTTCACAA Insertion Pathogenic 988858 GRCh37: 18:48584827-48584828
GRCh38: 18:51058457-51058458
18 VWF NM_000552.4(VWF):c.4121G>A (p.Arg1374His) SNV Pathogenic 100330 rs61750072 GRCh37: 12:6128463-6128463
GRCh38: 12:6019297-6019297
19 LOC106627981 , GBA NM_000157.4(GBA):c.653G>A (p.Trp218Ter) SNV Pathogenic 632834 rs867929413 GRCh37: 1:155208033-155208033
GRCh38: 1:155238242-155238242
20 FLI1 NM_002017.5(FLI1):c.992_995del (p.Asn331fs) Deletion Pathogenic 424634 rs1064797085 GRCh37: 11:128680515-128680518
GRCh38: 11:128810620-128810623
21 FGG NM_021870.3(FGG):c.331A>T (p.Lys111Ter) SNV Pathogenic 626954 rs1578812509 GRCh37: 4:155533027-155533027
GRCh38: 4:154611875-154611875
22 F11 NM_000128.3(F11):c.400C>T (p.Gln134Ter) SNV Pathogenic 188913 rs756908183 GRCh37: 4:187195344-187195344
GRCh38: 4:186274190-186274190
23 VWF NM_000552.4(VWF):c.7390C>T (p.Arg2464Cys) SNV Pathogenic 100467 rs61751286 GRCh37: 12:6085324-6085324
GRCh38: 12:5976158-5976158
24 F8 NM_000132.3(F8):c.5123G>A (p.Arg1708His) SNV Pathogenic 10266 rs111033614 GRCh37: X:154156942-154156942
GRCh38: X:154928667-154928667
25 F7 NM_019616.4(F7):c.781C>T (p.Arg261Trp) SNV Pathogenic 627147 rs779589651 GRCh37: 13:113772768-113772768
GRCh38: 13:113118454-113118454
26 RUNX1 NM_001754.5(RUNX1):c.508+1G>T SNV Pathogenic 988808 GRCh37: 21:36252853-36252853
GRCh38: 21:34880556-34880556
27 RUNX1 NM_001754.5(RUNX1):c.98-1G>A SNV Pathogenic 988809 GRCh37: 21:36259394-36259394
GRCh38: 21:34887097-34887097
28 ETV6 NM_001987.5(ETV6):c.1288C>T (p.Arg430Ter) SNV Pathogenic 988827 GRCh37: 12:12043909-12043909
GRCh38: 12:11890975-11890975
29 RUNX1 NM_001754.5(RUNX1):c.317G>A (p.Trp106Ter) SNV Pathogenic 988835 GRCh37: 21:36259174-36259174
GRCh38: 21:34886877-34886877
30 RUNX1 NM_001754.5(RUNX1):c.351+1G>T SNV Pathogenic 988837 GRCh37: 21:36259139-36259139
GRCh38: 21:34886842-34886842
31 MYH9 NM_002473.5(MYH9):c.5797C>T (p.Arg1933Ter) SNV Pathogenic 14072 rs80338835 GRCh37: 22:36678800-36678800
GRCh38: 22:36282754-36282754
32 MYH9 NM_002473.5(MYH9):c.3493C>T (p.Arg1165Cys) SNV Pathogenic 14074 rs80338829 GRCh37: 22:36691115-36691115
GRCh38: 22:36295069-36295069
33 F11 NM_000128.3(F11):c.403G>T (p.Glu135Ter) SNV Pathogenic 11891 rs121965063 GRCh37: 4:187195347-187195347
GRCh38: 4:186274193-186274193
34 LOC106627981 , GBA NM_000157.4(GBA):c.1246G>A (p.Gly416Ser) SNV Pathogenic 4327 rs121908311 GRCh37: 1:155205614-155205614
GRCh38: 1:155235823-155235823
35 F7 NM_019616.4(F7):c.1325del (p.Pro442fs) Deletion Likely pathogenic 626999 rs750457207 GRCh37: 13:113773309-113773309
GRCh38: 13:113118995-113118995
36 F7 NM_019616.4(F7):c.995C>T (p.Ala332Val) SNV Likely pathogenic 12076 rs36209567 GRCh37: 13:113772982-113772982
GRCh38: 13:113118668-113118668
37 RUNX1 NM_001754.5(RUNX1):c.403G>A (p.Gly135Ser) SNV Likely pathogenic 988857 GRCh37: 21:36252959-36252959
GRCh38: 21:34880662-34880662
38 RUNX1 NM_001754.4(RUNX1):c.593A>T (p.Asp198Val) SNV Likely pathogenic 627342 rs1569061786 GRCh37: 21:36231791-36231791
GRCh38: 21:34859494-34859494
39 RUNX1 NM_001754.5(RUNX1):c.1270T>G (p.Ser424Ala) SNV Likely pathogenic 988867 GRCh37: 21:36164605-36164605
GRCh38: 21:34792308-34792308
40 ETV6 NM_001987.5(ETV6):c.313C>T (p.Arg105Ter) SNV Likely pathogenic 988846 GRCh37: 12:11992223-11992223
GRCh38: 12:11839289-11839289
41 RUNX1 NM_001754.5(RUNX1):c.1256T>G (p.Val419Gly) SNV Likely pathogenic 988847 GRCh37: 21:36164619-36164619
GRCh38: 21:34792322-34792322
42 RUNX1 NM_001754.5(RUNX1):c.1270T>C (p.Ser424Pro) SNV Likely pathogenic 970259 GRCh37: 21:36164605-36164605
GRCh38: 21:34792308-34792308
43 FGG NM_021870.3(FGG):c.323C>G (p.Ala108Gly) SNV Likely pathogenic 547969 rs148685782 GRCh37: 4:155533035-155533035
GRCh38: 4:154611883-154611883
44 VWF NM_000552.4(VWF):c.2561G>A (p.Arg854Gln) SNV Likely pathogenic 296 rs41276738 GRCh37: 12:6143978-6143978
GRCh38: 12:6034812-6034812
45 VWF NM_000552.4(VWF):c.5278G>A (p.Val1760Ile) SNV Likely pathogenic 100422 rs61750604 GRCh37: 12:6125715-6125715
GRCh38: 12:6016549-6016549
46 VWF NM_000552.4(VWF):c.5851A>G (p.Thr1951Ala) SNV Likely pathogenic 619971 rs144072210 GRCh37: 12:6105380-6105380
GRCh38: 12:5996214-5996214
47 RUNX1 NM_001754.5(RUNX1):c.586A>G (p.Thr196Ala) SNV Likely pathogenic 988811 GRCh37: 21:36231798-36231798
GRCh38: 21:34859501-34859501
48 PTPN11 NM_002834.5(PTPN11):c.922A>G (p.Asn308Asp) SNV Likely pathogenic 13326 rs28933386 GRCh37: 12:112915523-112915523
GRCh38: 12:112477719-112477719
49 RUNX1 NM_001754.4(RUNX1):c.611G>A (p.Arg204Gln) SNV Likely pathogenic 561253 rs1569061762 GRCh37: 21:36231773-36231773
GRCh38: 21:34859476-34859476
50 PROS1 NM_000313.3(PROS1):c.284G>A (p.Gly95Glu) SNV Likely pathogenic 161354 rs144526169 GRCh37: 3:93629525-93629525
GRCh38: 3:93910681-93910681

Expression for Hemorrhagic Disease

Search GEO for disease gene expression data for Hemorrhagic Disease.

Pathways for Hemorrhagic Disease

Pathways related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.03 VWF SERPINF2 P2RY12 ITGA2B FGG FGA
2
Show member pathways
12.61 FGG FGA F9 F8 F7 F11
3
Show member pathways
12.1 VWF ITGA2B FGG FGA
4
Show member pathways
11.95 VWF ITGA2B FGG FGA
5
Show member pathways
11.87 VWF ITGA2B FGG FGA
6 11.81 VWF P2RY12 ITGA2B FGG FGA
7
Show member pathways
11.76 VWF SERPINF2 FGG FGA F9 F8
8
Show member pathways
11.66 VWF ITGA2B FGG FGA
9 11.39 VWF SERPINF2 FGG FGA F9 F8
10 11.33 RUNX1 ITGA2B FLI1
11 11.26 VWF P2RY12 ITGA2B FGG FGA
12 10.69 F9 F7

GO Terms for Hemorrhagic Disease

Cellular components related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.13 VWF SERPINF2 FGG FGA F9 F8
2 extracellular exosome GO:0070062 10.11 VWF SERPINF2 MYH9 ITGA2B GBA FGG
3 extracellular space GO:0005615 10.07 VWF SERPINF2 GBA FGG FGA F9
4 cell surface GO:0009986 9.91 SERPINF2 P2RY12 ITGA2B FGG FGA ADAMTS13
5 collagen-containing extracellular matrix GO:0062023 9.8 VWF SERPINF2 FGG FGA F9 F7
6 blood microparticle GO:0072562 9.71 SERPINF2 ITGA2B FGG FGA
7 endoplasmic reticulum lumen GO:0005788 9.63 FGG FGA F9 F8 F7 ADAMTS13
8 platelet alpha granule GO:0031091 9.43 VWF FGG FGA
9 fibrinogen complex GO:0005577 9.13 SERPINF2 FGG FGA
10 platelet alpha granule lumen GO:0031093 9.02 VWF SERPINF2 FGG FGA F8

Biological processes related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.91 VWF ITGA2B FGG FGA ADAMTS13
2 platelet degranulation GO:0002576 9.8 VWF SERPINF2 ITGA2B FGG FGA F8
3 cell-matrix adhesion GO:0007160 9.78 ITGA2B FGG FGA ADAMTS13
4 integrin-mediated signaling pathway GO:0007229 9.74 MYH9 ITGA2B ADAMTS13
5 blood coagulation, intrinsic pathway GO:0007597 9.67 VWF F9 F8 F11
6 platelet aggregation GO:0070527 9.65 P2RY12 MYH9 ITGA2B FGG FGA
7 fibrinolysis GO:0042730 9.63 SERPINF2 FGG FGA
8 platelet activation GO:0030168 9.63 VWF P2RY12 FGG FGA F8 ADAMTS13
9 hematopoietic stem cell proliferation GO:0071425 9.61 RUNX1 GBA ETV6
10 blood coagulation GO:0007596 9.61 VWF P2RY12 FGG FGA F9 F8
11 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.58 FGG FGA
12 plasminogen activation GO:0031639 9.58 FGG FGA F11
13 protein polymerization GO:0051258 9.56 FGG FGA
14 response to thyroid hormone GO:0097066 9.55 GBA F7
15 positive regulation of peptide hormone secretion GO:0090277 9.54 FGG FGA
16 blood coagulation, fibrin clot formation GO:0072378 9.52 FGG FGA
17 platelet maturation GO:0036345 9.49 SLFN14 FGG
18 hemostasis GO:0007599 9.32 VWF P2RY12 FLI1 FGG FGA F9

Molecular functions related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endopeptidase activity GO:0004175 8.8 F9 F7 ADAMTS13

Sources for Hemorrhagic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....